Chronic cirrhotic hepatitis B patients with a high incidence of hepatic decompensation after viral breakthrough with lamivudine-resistant mutants and during rescue treatment

References

• Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256–63
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61–8
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172–80
   PubMed Web of Science ®Google Scholar
• Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889–96
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847–51
   PubMed Web of Science ®Google Scholar
• Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527–32
   PubMed Web of Science ®Google Scholar
• Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567–72
   PubMed Web of Science ®Google Scholar
• Ahn SH, Chang YJ, Oh SN, Choi DW, Baek SJ, Jeong WS, et al. Clinical outcome in cases of viral breakthrough during lamivudine therapy in chronic hepatitis B patients. Taehan Kan Hakhoe Chi 2002; 8: 389–96
   PubMedGoogle Scholar
• Park CB, Lim HJ, Yun BC, Lee SU, Han BH. The clinical meaning of the emergence of viral breakthrough during lamivudine treatment in patients with hepatitis B virus related chronic liver disease. Korean J Hepatol 2004; 10: 108–16
   PubMedGoogle Scholar
• Kim JK, Hwang SG, Park H, Choi HY, Cho HJ, Ko KH, et al. Clinical outcomes after discontinuation of Lamivudine in chronic hepatitis B patients with lamivudine resistant HBV mutant. Korean J Hepatol 2005; 11: 227–42
   PubMedGoogle Scholar
• Liaw YF., Impact of YMDD, mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001; 12(Suppl 1)67–71
   PubMedGoogle Scholar
• Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther 2004; 19: 323–9
   PubMedGoogle Scholar
• Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 2002; 37: 366–9
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414–9
   PubMed Web of Science ®Google Scholar
• Peters MG, Hann HW H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91–101
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198–209
   PubMed Web of Science ®Google Scholar
• Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307–13
   PubMed Web of Science ®Google Scholar
• Di Marco V, Di Stefano R, Ferraro D, Almasio PL, Bonura C, et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 2005; 10: 431–9
   PubMed Web of Science ®Google Scholar
• Kim KM, Choi WB, Lim YS, Lee HC, Chung YH, Lee YS, et al. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. J Korean Med Sci 2005; 20: 821–8
   PubMedGoogle Scholar
• Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat 2006; 13: 250–5
   PubMed Web of Science ®Google Scholar
• Kim YS KS, Jin HY, Ma MS, Lee SO, Lee ST, et al. Efficacy of 1-year lamivudine treatment in the patient of chronic B hepatitis and liver cirrhosis. Korean J Hepatol 2001; 7: 171–80
   Google Scholar
• Lok AS, McMahon BJ., Chronic hepatitis B. Hepatology 2007; 45: 507–39
   PubMed Web of Science ®Google Scholar
• Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283–90
   PubMed Web of Science ®Google Scholar
• Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 1488–95
   PubMed Web of Science ®Google Scholar
• Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385–91
   PubMed Web of Science ®Google Scholar
• Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81–90
   PubMed Web of Science ®Google Scholar
• van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318–25
   PubMed Web of Science ®Google Scholar
• Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391–8
   PubMed Web of Science ®Google Scholar
• Yuen MF, Kato T, Mizokami M, Chan AO, Yuen JC, Yuan HJ, et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003; 39: 850–5
   PubMedGoogle Scholar
• Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57–63
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263–70
   PubMed Web of Science ®Google Scholar
• Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121–9
   PubMed Web of Science ®Google Scholar
• Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883–91
   PubMed Web of Science ®Google Scholar